244 related articles for article (PubMed ID: 12772815)
1. Brimonidine Purite and bimatoprost compared with timolol and latanoprost in patients with glaucoma and ocular hypertension.
Netland PA; Michael M; Rosner SA; Katzman B; Macy JI
Adv Ther; 2003; 20(1):20-30. PubMed ID: 12772815
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
García-López A; Paczka JA; Jiménez-Román J; Hartleben C
BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
[TBL] [Abstract][Full Text] [Related]
3. Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension.
Day DG; Hollander DA
Curr Med Res Opin; 2008 May; 24(5):1435-42. PubMed ID: 18402717
[TBL] [Abstract][Full Text] [Related]
4. Bimatoprost versus latanoprost in lowering intraocular pressure in glaucoma and ocular hypertension: results from parallel-group comparison trials.
Simmons ST; Dirks MS; Noecker RJ
Adv Ther; 2004; 21(4):247-62. PubMed ID: 15605619
[TBL] [Abstract][Full Text] [Related]
5. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial.
Walters TR; DuBiner HB; Carpenter SP; Khan B; VanDenburgh AM;
Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S26-35. PubMed ID: 15016559
[TBL] [Abstract][Full Text] [Related]
6. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
Topouzis F; Melamed S; Danesh-Meyer H; Wells AP; Kozobolis V; Wieland H; Andrew R; Wells D
Eur J Ophthalmol; 2007; 17(2):183-90. PubMed ID: 17415690
[TBL] [Abstract][Full Text] [Related]
7. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma.
Noecker RS; Dirks MS; Choplin NT; Bernstein P; Batoosingh AL; Whitcup SM;
Am J Ophthalmol; 2003 Jan; 135(1):55-63. PubMed ID: 12504698
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D
Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
Stewart WC; Konstas AG; Nelson LA; Kruft B
Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
[TBL] [Abstract][Full Text] [Related]
10. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.
Easthope SE; Perry CM
Drugs Aging; 2002; 19(3):231-48. PubMed ID: 12027782
[TBL] [Abstract][Full Text] [Related]
11. A 6-month randomized clinical trial of bimatoprost 0.03% versus the association of timolol 0.5% and latanoprost 0.005% in glaucomatous patients.
Manni G; Centofanti M; Parravano M; Oddone F; Bucci MG
Graefes Arch Clin Exp Ophthalmol; 2004 Sep; 242(9):767-70. PubMed ID: 15241611
[TBL] [Abstract][Full Text] [Related]
12. A comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open-angle glaucoma.
Martinez A; Sanchez M
Curr Med Res Opin; 2007 May; 23(5):1025-32. PubMed ID: 17519068
[TBL] [Abstract][Full Text] [Related]
13. Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension.
Mundorf T; Noecker RJ; Earl M
Adv Ther; 2007; 24(2):302-9. PubMed ID: 17565920
[TBL] [Abstract][Full Text] [Related]
14. Comparison of brimonidine/latanoprost and timolol/dorzolamide: two randomized, double-masked, parallel clinical trials.
Zabriskie N; Netland PA;
Adv Ther; 2003; 20(2):92-100. PubMed ID: 12836809
[TBL] [Abstract][Full Text] [Related]
15. Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials.
Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Suganami H; Araie M;
JAMA Ophthalmol; 2015 Jul; 133(7):755-61. PubMed ID: 25880207
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost.
DuBiner H; Cooke D; Dirks M; Stewart WC; VanDenburgh AM; Felix C
Surv Ophthalmol; 2001 May; 45 Suppl 4():S353-60. PubMed ID: 11434938
[TBL] [Abstract][Full Text] [Related]
17. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering.
Simmons ST; Earl ML;
Ophthalmology; 2002 Feb; 109(2):307-14; discussion 314-5. PubMed ID: 11825814
[TBL] [Abstract][Full Text] [Related]
18. Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma. ALPHAGAN/XALATAN Study Group.
Simmons ST; Samuelson TW
Clin Ther; 2000 Apr; 22(4):388-99. PubMed ID: 10823361
[TBL] [Abstract][Full Text] [Related]
19. Latanoprost or brimonidine as treatment for elevated intraocular pressure: multicenter trial in the United States.
Camras CB; Sheu WP;
J Glaucoma; 2005 Apr; 14(2):161-7. PubMed ID: 15741820
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial.
DuBiner HB; Mroz M; Shapiro AM; Dirks MS;
Clin Ther; 2001 Dec; 23(12):1969-83. PubMed ID: 11813932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
